Oropharyngeal administration of silica in Swiss mice: A robust and reproducible model of occupational pulmonary fibrosis

Pulmonary Pharmacology and Therapeutics

Volumn 51, Issue , 2018, Pages 32-40

  Karkale, Sachin ^a   Khurana, Amit ^a   Saifi, Mohd Aslam ^a   Godugu, Chandraiah ^a   Talla, Venu ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

ECM; EMT; Intratracheal; Oropharyngeal; Pulmonary fibrosis; Silicosis

Indexed keywords

ALBUMIN; ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; GLUTATHIONE; HYDROXYPROLINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LACTATE DEHYDROGENASE; MALONALDEHYDE; NERVE CELL ADHESION MOLECULE; SILICON DIOXIDE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; VIMENTIN; CYTOKINE;

ALBUMIN LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT LOSS; CONTROLLED STUDY; CYTOLOGY; ENZYME ACTIVITY; FIBROGENESIS; LUNG; LUNG LAVAGE; LUNG STRUCTURE; LUNG WEIGHT; LYMPHOCYTE COUNT; MACROPHAGE; MALE; MOUSE; NEUTROPHIL COUNT; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SILICOSIS; ANIMAL; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODEL; LUNG FIBROSIS; METABOLISM; OCCUPATIONAL DISEASE; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGY; REPRODUCIBILITY; VALIDATION STUDY;

ADMINISTRATION, ORAL; ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; CYTOKINES; DISEASE MODELS, ANIMAL; HYDROXYPROLINE; MALE; MICE; NITROSATIVE STRESS; OCCUPATIONAL DISEASES; OXIDATIVE STRESS; PULMONARY FIBROSIS; REPRODUCIBILITY OF RESULTS; SILICON DIOXIDE;

EID: 85049352966     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2018.06.003     Document Type: Article

References (33)

1. Nalysnyk, L., Cid-Ruzafa, J., Rotella, P., Esser, D., Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur. Respir. Rev. 21:126 (2012), 355–361.
2. Reynolds, C., Vinnikov, D., Murgia, N., Annesi-Maesano, I., Balmes, J., Fishwick, D., Miedinger, D., Cummings, R., Naidoo, C.R., Sigsgaard, T., Occupational contribution to idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med., 195, 2017 A7009.
3. Johannson, K.A., Vittinghoff, E., Lee, K., Balmes, J.R., Ji, W., Kaplan, G.G., Kim, D.S., Collard, H.R., Acute exacerbation of idiopathic pulmonary fibrosis associated with air pollution exposure. Eur. Respir. J. 43:4 (2014), 1124–1131.
4. Conti, S., Harari, S., Caminati, A., Zanobetti, A., Schwartz, J.D., Bertazzi, P.A., Cesana, G., Madotto, F., The association between air pollution and the incidence of idiopathic pulmonary fibrosis in Northern Italy. Eur. Respir. J., 51(1), 2018, 1700397.
5. Johannson, K.A., Balmes, J.R., Collard, H.R., Air pollution exposure: a novel environmental risk factor for interstitial lung disease?. Chest 147:4 (2015), 1161–1167.
6. Sesé L., Nunes, H., Cottin, V., Sanyal, S., Didier, M., Carton, Z., Israel-Biet, D., Crestani, B., Cadranel, J., Wallaert, B., Role of atmospheric pollution on the natural history of idiopathic pulmonary fibrosis. Thorax 73:2 (2018), 145–150.
7. Hutchinson, J., Fogarty, A., Hubbard, R., McKeever, T., Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur. Respir. J. 46:3 (2015), 795–806.
8. Raghu, G., Chen, S.-Y., Hou, Q., Yeh, W.-S., Collard, H.R., Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18–64 years old. Eur. Respir. J. 48:1 (2016), 179–186.
9. Raghu, G., Chen, S.-Y., Yeh, W.-S., Maroni, B., Li, Q., Lee, Y.-C., Collard, H.R., Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001–11. Lancet. Respir. Med. 2:7 (2014), 566–572.
10. Ding, M., Chen, F., Shi, X., Yucesoy, B., Mossman, B., Vallyathan, V., Diseases caused by silica: mechanisms of injury and disease development. Int. Immunopharm. 2:2–3 (2002), 173–182.
11. Mossman, B.T., Churg, A., Mechanisms in the pathogenesis of asbestosis and silicosis. Am. J. Respir. Crit. Care Med. 157:5 (1998), 1666–1680.
12. Rimal, B., Greenberg, A.K., Rom, W.N., Basic pathogenetic mechanisms in silicosis: current understanding. Curr. Opin. Pulm. Med. 11:2 (2005), 169–173.
13. Leung, C.C., Yu, I.T.S., Chen, W., Silicosis. Lancet 379:9830 (2012), 2008–2018.
14. Castranova, V., Vallyathan, V., Silicosis and coal workers’ pneumoconiosis. Environ. Health Perspect. 108:Suppl 4 (2000), 675–680.
15. Bowden, D., Adamson, I., The role of cell injury and the continuing inflammatory response in the generation of silicotic pulmonary fibrosis. J. Pathol. 144:3 (1984), 149–161.
16. Heppleston, A., Atypical reaction to inhaled silica. Nature, 213(5072), 1967, 199.
17. Heppleston, A., Styles, J., Activity of a macrophage factor in collagen formation by silica. Nature 214:5087 (1967), 521–523.
18. Heppleston, A., The fibrogenic achon of silica. Br. Med. Bull. 25:3 (1969), 282–287.
19. Lakatos, H.F., Burgess, H.A., Thatcher, T.H., Redonnet, M.R., Hernady, E., Williams, J.P., Sime, P.J., Oropharyngeal aspiration of a silica suspension produces a superior model of silicosis in the mouse when compared to intratracheal instillation. Exp. Lung Res. 32:5 (2006), 181–199.
20. Egger, C., Cannet, C., Gérard, C., Jarman, E., Jarai, G., Feige, A., Suply, T., Micard, A., Dunbar, A., Tigani, B., Administration of bleomycin via the oropharyngeal aspiration route leads to sustained lung fibrosis in mice and rats as quantified by UTE-MRI and histology. PLoS One, 8(5), 2013 e63432.
21. Bale, S., Sunkoju, M., Reddy, S.S., Swamy, V., Godugu, C., Oropharyngeal aspiration of bleomycin: an alternative experimental model of pulmonary fibrosis developed in Swiss mice. Indian Journal of Pharmacology 48:6 (2016), 643–651.
22. Reddy, D.R., Khurana, A., Bale, S., Ravirala, R., Reddy, V.S.S., Mohankumar, M., Godugu, C., Natural flavonoids silymarin and quercetin improve the brain distribution of co-administered P-gp substrate drugs. SpringerPlus 5:1 (2016), 1618–1627.
23. Rabolli, V., Re, S.L., Uwambayinema, F., Yakoub, Y., Lison, D., Huaux, F., Lung fibrosis induced by crystalline silica particles is uncoupled from lung inflammation in NMRI mice. Toxicol. Lett. 203:2 (2011), 127–134.
24. Kim, M.S., Kim, S.H., Jeon, D., Kim, H.Y., Lee, K., Changes in expression of cytokines in polyhexamethylene guanidine-induced lung fibrosis in mice: comparison of bleomycin-induced lung fibrosis. Toxicology 393 (2018), 185–192.
25. Ohkawa, H., Ohishi, N., Yagi, K., Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95:2 (1979), 351–358.
26. Kumar, G.S., Kulkarni, A., Khurana, A., Kaur, J., Tikoo, K., Selenium nanoparticles involve HSP-70 and SIRT1 in preventing the progression of type 1 diabetic nephropathy. Chem. Biol. Interact. 223 (2014), 125–133.
27. Moron, M.S., Depierre, J.W., Mannervik, B., Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochim. Biophys. Acta Gen. Subj. 582:1 (1979), 67–78.
28. Woessner, J. Jr., The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch. Biochem. Biophys. 93:2 (1961), 440–447.
29. Sangomla, S., Saifi, M.A., Khurana, A., Godugu, C., Nanoceria ameliorates doxorubicin induced cardiotoxicity: possible mitigation via reduction of oxidative stress and inflammation. J. Trace Elem. Med. Biol. 47 (2018), 53–62.
30. Bale, S., Khurana, A., Reddy, A.S.S., Singh, M., Godugu, C., Overview on therapeutic applications of microparticulate drug delivery systems. Crit. Rev. Ther. Drug Carrier Syst. 33:4 (2016), 309–361.
31. Khurana, A., Saifi, M., Godugu, C., Nanoceria Reduces Oxidative Stress, Inflammation and Display Anti-fibrotic Properties in Animal Models of Chronic Pancreatitis, Pancreas. 2017, lippincott williams & wilkins two commerce sq, 2001 market st, Philadelphia, 1411–1412 PA 19103 USA.
32. Trivedi, R., Redente, E.F., Thakur, A., Riches, D.W., Kompella, U.B., Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice. Nanotechnology, 23(50), 2012, 505101.
33. Garbuzenko, O.B., Ivanova, V., Kholodovych, V., Reimer, D.C., Reuhl, K.R., Yurkow, E., Adler, D., Minko, T., Combinatorial treatment of idiopathic pulmonary fibrosis using nanoparticles with prostaglandin E and siRNA (s), Nanomedicine: Nanotechnology. Biol. Med. 13:6 (2017), 1983–1992.